Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US68622V1061
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00ZQRGW24
OGN
Organon & Co
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Drug Manufacturers - General · THEMEFOLIO: $HLTH
NAME
Organon & Co
ISIN
US68622V1061
TICKER
OGN
MIC
XNYS
REUTERS
OGN.N
BLOOMBERG
OGN US
Mo., 27.04.2026       Organon & Co.
US68622V1061

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited for $14.00 per share.Halper Sadeh encourages Organon shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or ...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 27.04.2026       Organon & Co.
US68622V1061

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shar...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will release its first quarter 2026 financial results on May 7, 2026, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect t...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that VTAMA cream was granted a strong, evidence-based recommendation by the American Academy of Dermatology (AAD) in their 2026 guidelines for the management and treatment of atopic dermatitis (AD)...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Organon & Co.
US68622V1061

SYDNEY, March 30, 2026 /PRNewswire/ -- Organon Asia Pacific Cluster today announced the 2026 Her Health Grant recipients for the Asia Pacific region, marking a significant milestone in efforts to strengthen and expand women's health initiatives across the region. The Her Health Grants are designed to support organizations that expand access, equit...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Organon & Co.
US68622V1061

SYDNEY, March 30, 2026 /PRNewswire/ -- Organon Asia Pacific Cluster today announced the 2026 Her Health Grant recipients for the Asia Pacific region, marking a significant milestone in efforts to strengthen and expand women's health initiatives across the region. The Her Health Grants are designed to support organizations that expand access, equit...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a post-hoc sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating the efficacy and safety of VTAMA cream versus vehicle in an oral session at the 2...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 27.02.2026       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma & Immunolog...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of thi...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Organon & Co.
US68622V1061

Das Instrument 7XP US68622V1061 ORGANON + CO. DL -,01 EQUITY wird cum Dividende/Zinsen gehandelt am 20.02.2026 und ex Dividende/Zinsen am 23.02.2026 The instrument 7XP US68622V1061 ORGANON + CO. DL -,01 EQUITY has its pre-dividend/interest day on 20.02.2026 and its ex-dividend/interest day on 23.02.2026...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 12.02.2026       Organon & Co.
US68622V1061

Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2025. “In 2025 we took action that demonstrated our commitment to improving the balance sheet and to building more financial flexibility,” said Joe Morrissey, Organon’s interim Chief Executive Officer. “In 2026 our primary objective is to main...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 29.01.2026       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its fourth quarter and full year 2025 financial results on February 12, 2026, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone exp...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 28.01.2026       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp. Please see our prior announcement for a summary of the transaction terms. Indications for Use The JA...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 17.01.2026       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON® (etonogestrel implant), which is indicated for use by women of reproductive pot...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 08.01.2026       Organon & Co.
US68622V1061

Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for pa...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 25.11.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN), announced today that Joe Morrissey, Interim Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd, 2025 at 10:00 a.m. ET. Investors, analysts, members of the media and the general pu...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 17.11.2025       Organon & Co.
US68622V1061

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 15.11.2025       Organon & Co.
US68622V1061

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Organon & Co. (NYSE: OGN). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 10.11.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alongside our talented team during this pivotal time for Organon,” said Joe Morrissey, Organon’s Interim Chief Executive Officer. “We are harnessing the company's many strengths, including a diverse portfolio that we expect...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 08.11.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global independent healthcare company with a focus on women’s health, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Orla...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Sa., 08.11.2025       Organon & Co.
US68622V1061

NEW YORK and NEW ORLEANS, Nov. 7, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), is investigating claims on behalf of investors of Organon & Co. (NYSE: OGN). Such investors are advised to contact KSF Manag...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 07.11.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading diagnostic and therapeutic medical technology company, for them to...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its third quarter 2025 financial results on November 10, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET. The webcast and conference call will be hosted by Carrie Cox, Organon’s Executive Board Chair; Joe Morri...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Organon & Co.
US68622V1061

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Organon & Co. (NYSE: OGN). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 27.10.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN) (“Organon” or “the company”) today announced that its Board of Directors has appointed the Company’s Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair t...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 19.09.2025       Organon & Co.
US68622V1061

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the referenc...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 09.09.2025       Organon & Co.
US68622V1061

NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Organon & Co. (NYSE: OGN) breached their fiduciary duties to shareholders. ...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 02.09.2025       Organon & Co.
US68622V1061

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference pr...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 13.08.2025       Organon & Co.
US68622V1061

SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Organon & Co. (NYSE: OGN). Investors who purchased shares of Organon & Co. (NY...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Organon & Co.
US68622V1061

NEW YORK  , July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are enc...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Organon & Co.
US68622V1061

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) and reminds investors of the July 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Fa...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Organon & Co.
US68622V1061

NEW YORK, July 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its second quarter 2025 financial results on August 5, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Accessing Second Quarter 2025 Financial Results Webcast Interested parties may access the live call vi...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 21.07.2025       Organon & Co.
US68622V1061

LOS ANGELES, July 21, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the federal securities laws. Shareholders who purchased the Company's securities between October 31, 2024 and April 30, 2025, inclusive (the "Class Period"),...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 21.07.2025       Organon & Co.
US68622V1061

LOS ANGELES, July 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. S...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 21.07.2025       Organon & Co.
US68622V1061

The Law Offices of Frank R. Cruz reminds investors of the upcoming July 22, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between November 3, 2022 to April 30, 2025, inclusive (the “Class P...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 21.07.2025       Organon & Co.
US68622V1061

LOS ANGELES, July 21, 2025 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the federal securities laws. Shareholders who purchased the Company's securities between October 31, 2024 and April 30, 2025, inclusive (the "Class Period")...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 21.07.2025       Organon & Co.
US68622V1061

NEW YORK, July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to cont...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 19.07.2025       Organon & Co.
US68622V1061

SAN DIEGO, July 18, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Organon & Co. (NYSE: OGN) publicly traded securities between November 3, 2022 and April 30, 2025, inclusive (the "Class Period").  Captioned Lerner v. Organon &...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 19.07.2025       Organon & Co.
US68622V1061

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in securities class action lawsuits against Organon & Co. (NYSE: OGN), if they purchased the Company’s securities between November 3, 2022 an...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 18.07.2025       Organon & Co.
US68622V1061

NEW YORK, July 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 17.07.2025       Organon & Co.
US68622V1061

NEW YORK, July 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between November 3, 2022 and April 30, 2025, both dates inclusive (th...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 17.07.2025       Organon & Co.
US68622V1061

NEW YORK, July 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encou...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 17.07.2025       Organon & Co.
US68622V1061

NEW YORK, July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to cont...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 17.07.2025       Organon & Co.
US68622V1061

PHILADELPHIA, July 17, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN) on behalf of purchasers of Organon securities between November 3, 2022 through April 30, 2025, inclusive (the "Class Period")....
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 15.07.2025       Organon & Co.
US68622V1061

SAN DIEGO, July 15, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Organon & Co. (NYSE: OGN) publicly traded securities between November 3, 2022 and April 30, 2025, both dates inclusive (the "Class Period").  Captioned Lerner v. Organon & Co.,...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 15.07.2025       Organon & Co.
US68622V1061

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Organon between October 31, 2024 and April 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 15.07.2025       Organon & Co.
US68622V1061

NEW YORK, July 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover...
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 14.07.2025       Organon & Co.
US68622V1061

PHILADELPHIA, July 14, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN) on behalf of purchasers of Organon securities between November 3, 2022 through April 30, 2025, inclusive (the "Class Period")....
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 14.07.2025       Organon & Co.
US68622V1061

LOS ANGELES, July 14, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Organon & Co. ("Organon" or the "Company") (NYSE: OGN)....
Zur Nachricht
Organon & Co.
Charts & Research Termsheets Terminal
Permalink